bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is listed today as bioAffinity Technologies, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2024 | $1 M | Private placement after listing | Under $2 million | equity, options | SEC | |
| Mar 2024 | $3 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Jul 2017 | $4 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
bioAffinity Technologies, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2024).
SEC Form D · Aug 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2024
That is all the official record says: bioAffinity Technologies, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of bioAffinity Technologies, Inc. are on record.
Investors#
4 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Harvey Sandler Revocable Trust | Other | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Mohsin Y. Meghji | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2023) | SEC Form 3 |
| Nathan M. Perlmutter | Person | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| Steven Girgenti | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2022) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 39 investors.
Largest shareholders today
Institutions holding bioAffinity Technologies, Inc. shares, as of Sep 30, 2026.
- HRT Financial LP$1 M5.02%
- Jane Street Group, LLC$0 M2.35%
- Virtu Financial LLC$0 M0.92%
- BlackRock, Inc.$0 M0.36%
- Vanguard Capital Management LLC$0 M0.20%
- UBS Group AG$0 M0.17%
- Vanguard Fiduciary Trust Co$0 M0.11%
- Allworth Financial LP$0 M0.04%
- Tower Research Capital LLC (TRC)$0 M0.02%
- Royal Bank Of Canada$0 M0.00%
- IFP Advisors, Inc$0 M0.00%
- Robinhood Markets, Inc.$0 M0.00%
- Russell Investments Group, Ltd.$0 M0.00%
- Pinnacle Financial Group, Inc.$0 M0.00%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Maria Zannes | Chief Executive Officer | Aug 2024 |
| Michael Dougherty | Chief Financial Officer | Aug 2024 |
| Timothy P. Zannes | Executive VP and Secretary | Aug 2024 |
| Vivienne Rebel | Chief Science and Medical Officer | Aug 2024 |
| Xavier Reveles | Chief Operating Officer | Aug 2024 |
| Steven P. Girgenti | Executive officer | Mar 2024 |
| Gary P. Rubin | Director | Aug 2024 |
| Jamie P. Platt | Director | Aug 2024 |
| Maria Zannes | Chief Executive Officer | Aug 2024 |
| Peter A. Knight | Director | Aug 2024 |
| Robert A. Anderson | Director | Aug 2024 |
| Roby P. Joyce | Director | Aug 2024 |
| Steven P. Girgenti | Director | Aug 2024 |
| Stuart A. Diamond | Director | Aug 2024 |
| Xavier Reveles | Chief Operating Officer | Aug 2024 |
| Barry Frankel | Director | Jul 2017 |
| Myron Holubiak | Director | Jul 2017 |
| Robert Anderson | Director | Jul 2017 |
| Steven Girgenti | Director | Jul 2017 |
Went public since 2022. Its SEC number is that of a company listed on a stock exchange.